Stockscreener 앱 받기
2.99
3.24%
-0.10
전일 마감가:
$3.09
열려 있는:
$3
하루 거래량:
50,930
Relative Volume:
0.66
시가총액:
$12.42M
수익:
-
순이익/손실:
$-4.74M
주가수익비율:
-3.9867
EPS:
-0.75
순현금흐름:
$-3.46M
1주 성능:
+7.55%
1개월 성능:
+21.54%
6개월 성능:
+4.18%
1년 성능:
-42.32%
1일 변동 폭
$2.80
$3.10
1주일 범위
$2.75
$3.1699
52주 변동 폭
$1.965
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
명칭
Lipella Pharmaceuticals Inc
전화
412-901-0315
주소
400 N LEXINGTON ST, PITTSBURGH
LIPO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.99 | 12.42M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc 주식(LIPO)의 최신 뉴스
LIPO Secures Continued Partnership with Cook MyoSite for Enhanced Product Development | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development - marketscreener.com
Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite - Contract Pharma
Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite - Investing.com
Lipella Pharmaceuticals Re-signs Manufacturing - GlobeNewswire
First-Ever Oral Lichen Planus Treatment Advances as Lipella Secures Key Manufacturing Deal - Stock Titan
Lipella Pharmaceuticals to appeal Nasdaq noncompliance warningPittsburgh Business Times - The Business Journals
Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
LIPO: Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data - TipRanks
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 - GlobeNewswire
Breakthrough Phase 2a Data: New LP-310 Treatment Cuts Oral Lichen Planus Pain by 65%, Exceeds Endpoints - Stock Titan
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com Australia
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World
Lipella Pharmaceuticals Inc (LIPO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):